Aledade and Aetna are partnering to bring population health to patients and greater accountability of total cost of care to providers, said Travis Broome, vice president of policy at Aledade.
Aledade and Aetna are partnering to bring population health to patients and greater accountability of total cost of care to providers, said Travis Broome, vice president of policy at Aledade.
Transcript
Aledade is partnering with Aetna to expand value-based care in 3 states. How will the partnership improve care and lower costs for patients? What is the partnership focusing on?
So, one of our big beliefs is that we want the total patient panel, right? You know, if we’re going to move away from the 15-minute blocks, it’s best if you can do that for everyone, so it’s always been a mission of Aledade to get as many of our practices' patients under value-based care models, as possible.
So, we work with tons of commercial payers now to that end. The Aetna partnership is one we’re excited about, because you mentioned it’s in 3 states now. Aetna and Aledade both have a national footprint, but at the end of the day it’s all about bringing population health to as many patients as we can, and you know, really when you think about total cost of care accountability, and what it means to be an ACO [accountable care organization], we think of it as excellence in primary care and excellence in population health.
Both of those things are enabled by great partnerships with payers from data—we just heard the CMS administrator talk about data underpins all this—certainly would agree with that from finical right. At the end of the day, these are all small businesses that stay in operation to, you know, partnerships in coordinating benefits for members. So, that is really our, they’re excited about all of our commercial partners for that reason because we want every patient of the practice to get excellence in primary care and excellence in population health and partnerships like the Aetna one make that possible.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More